CN109561680B - 泛酸激酶的小分子调节剂 - Google Patents

泛酸激酶的小分子调节剂 Download PDF

Info

Publication number
CN109561680B
CN109561680B CN201780043423.3A CN201780043423A CN109561680B CN 109561680 B CN109561680 B CN 109561680B CN 201780043423 A CN201780043423 A CN 201780043423A CN 109561680 B CN109561680 B CN 109561680B
Authority
CN
China
Prior art keywords
another aspect
alkyl
compounds
halogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780043423.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN109561680A (zh
Inventor
L·K·夏尔马
R·E·李
C·O·罗克
S·贾可斯基
M·K·云
C·苏布兰马尼安
J·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St. Jude Children's Research Hospital
Original Assignee
St. Jude Children's Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60783428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109561680(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by St. Jude Children's Research Hospital filed Critical St. Jude Children's Research Hospital
Publication of CN109561680A publication Critical patent/CN109561680A/zh
Application granted granted Critical
Publication of CN109561680B publication Critical patent/CN109561680B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780043423.3A 2016-06-23 2017-06-23 泛酸激酶的小分子调节剂 Active CN109561680B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662354012P 2016-06-23 2016-06-23
US62/354,012 2016-06-23
PCT/US2017/039037 WO2017223474A1 (en) 2016-06-23 2017-06-23 Small molecule modulators of pantothenate kinases

Publications (2)

Publication Number Publication Date
CN109561680A CN109561680A (zh) 2019-04-02
CN109561680B true CN109561680B (zh) 2021-07-13

Family

ID=60783428

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780043423.3A Active CN109561680B (zh) 2016-06-23 2017-06-23 泛酸激酶的小分子调节剂

Country Status (13)

Country Link
US (2) US10899734B2 (enExample)
EP (1) EP3474667A4 (enExample)
JP (1) JP7078555B2 (enExample)
KR (1) KR102459256B1 (enExample)
CN (1) CN109561680B (enExample)
AU (1) AU2017281907B2 (enExample)
DO (1) DOP2018000293A (enExample)
IL (1) IL263649B (enExample)
MX (1) MX383697B (enExample)
SA (1) SA518400696B1 (enExample)
SG (1) SG11201811023UA (enExample)
WO (1) WO2017223474A1 (enExample)
ZA (1) ZA201808099B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383697B (es) 2016-06-23 2025-03-14 St Jude Childrens Res Hospital Inc Moduladores de moleculas peque?as de pantotenato cinasas
WO2019133632A1 (en) * 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Methods of treating disorders associated with castor
MX2020006754A (es) * 2017-12-27 2021-01-29 St Jude Childrens Res Hospital Inc Moduladores de molécula pequeña de pantotenato-cinasas.
WO2020017569A1 (ja) * 2018-07-17 2020-01-23 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
US12534451B2 (en) * 2019-03-27 2026-01-27 St. Jude Children's Research Hospital, Inc. Small molecule modulators of PanK
US20220226299A1 (en) * 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic acetylcholine m1 receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
EP4262814A4 (en) * 2020-12-16 2025-02-26 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
JP2025528119A (ja) * 2022-08-08 2025-08-26 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての複素環式アミド及び尿素化合物
WO2026012398A1 (zh) * 2024-07-09 2026-01-15 长春金赛药业有限责任公司 泛酸激酶pank小分子调节剂、药物组合物及其用途
CN119745886B (zh) * 2025-01-20 2026-04-14 中国药科大学 4-异丙苯基乙酰哌嗪在制备抗阿尔茨海默病药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1474810A (zh) * 2000-09-14 2004-02-11 ���鹫˾ 取代脲,神经肽yy5受体拮抗剂
CN1753890A (zh) * 2002-12-24 2006-03-29 欧洲凯尔特公司 具有mglur1－和mglur5－拮抗活性的苯并唑类哌嗪衍生物
CN1835751A (zh) * 2003-06-12 2006-09-20 欧洲凯尔蒂克公司 用于治疗疼痛的治疗剂
CN102143958A (zh) * 2008-07-18 2011-08-03 诺瓦提斯公司 作为smo抑制剂的哒嗪衍生物
US8975398B2 (en) * 2012-05-11 2015-03-10 Abbvie Inc. NAMPT inhibitors
CN105228995A (zh) * 2013-03-13 2016-01-06 詹森药业有限公司 取代的哌啶化合物以及它们作为食欲素受体调节剂的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216212A (en) 1978-06-08 1980-08-05 The Procter & Gamble Company Pyrazolidine anti-inflammatory composition and methods of use
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
KR20060037410A (ko) * 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피리다진 유도체 및 그의 치료제로서의 용도
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
US20080153811A1 (en) 2006-11-07 2008-06-26 Joseph Barbosa Methods of Treating Cognitive Impairment and Dementia
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
CA2692502C (en) 2007-07-05 2016-03-01 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
EP2414505B1 (en) 2009-04-02 2019-05-22 University of Florida Research Foundation, Inc. Engineering the pathway for succinate production
US8741611B2 (en) 2009-09-01 2014-06-03 Novozymes, Inc. Methods for improving malic acid production in filamentous fungi
US9187772B2 (en) 2010-09-01 2015-11-17 University Of Florida Research Foundation, Inc. L-malate production by metabolically engineered escherichia coli
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
WO2013004642A1 (en) 2011-07-01 2013-01-10 Remynd Nv 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases
WO2016168619A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
MX383697B (es) 2016-06-23 2025-03-14 St Jude Childrens Res Hospital Inc Moduladores de moleculas peque?as de pantotenato cinasas
MX2020006754A (es) 2017-12-27 2021-01-29 St Jude Childrens Res Hospital Inc Moduladores de molécula pequeña de pantotenato-cinasas.
WO2019133632A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Methods of treating disorders associated with castor
WO2019133634A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
WO2020017569A1 (ja) 2018-07-17 2020-01-23 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
EP4262814A4 (en) 2020-12-16 2025-02-26 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1474810A (zh) * 2000-09-14 2004-02-11 ���鹫˾ 取代脲,神经肽yy5受体拮抗剂
CN1753890A (zh) * 2002-12-24 2006-03-29 欧洲凯尔特公司 具有mglur1－和mglur5－拮抗活性的苯并唑类哌嗪衍生物
CN1835751A (zh) * 2003-06-12 2006-09-20 欧洲凯尔蒂克公司 用于治疗疼痛的治疗剂
CN102143958A (zh) * 2008-07-18 2011-08-03 诺瓦提斯公司 作为smo抑制剂的哒嗪衍生物
US8975398B2 (en) * 2012-05-11 2015-03-10 Abbvie Inc. NAMPT inhibitors
CN105228995A (zh) * 2013-03-13 2016-01-06 詹森药业有限公司 取代的哌啶化合物以及它们作为食欲素受体调节剂的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists";Laykea Tafesse 等;《Bioorganic & Medicinal Chemistry Letters》;20041115;第14卷(第22期);第5514-5515页、表1 *

Also Published As

Publication number Publication date
SA518400696B1 (ar) 2023-01-09
WO2017223474A1 (en) 2017-12-28
JP7078555B2 (ja) 2022-05-31
US12552765B2 (en) 2026-02-17
EP3474667A4 (en) 2019-11-27
AU2017281907B2 (en) 2021-10-21
RU2019101613A (ru) 2020-07-23
IL263649A (en) 2019-01-31
IL263649B (en) 2022-04-01
BR112018076441A2 (pt) 2019-04-09
KR102459256B1 (ko) 2022-10-25
NZ749147A (en) 2024-04-26
CA3025260A1 (en) 2017-12-28
US20190300499A1 (en) 2019-10-03
JP2019518764A (ja) 2019-07-04
DOP2018000293A (es) 2019-04-15
ZA201808099B (en) 2019-07-31
KR20190022620A (ko) 2019-03-06
US10899734B2 (en) 2021-01-26
RU2019101613A3 (enExample) 2020-12-03
AU2017281907A1 (en) 2019-01-03
MX2018015170A (es) 2019-07-04
CN109561680A (zh) 2019-04-02
US20210246113A1 (en) 2021-08-12
EP3474667A1 (en) 2019-05-01
SG11201811023UA (en) 2019-01-30
MX383697B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
US12552765B2 (en) Small molecule modulators of pantothenate kinases
CN103889962B (zh) 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
CN111818922B (zh) 泛酸激酶的小分子调节剂
US9296703B2 (en) Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
US12534451B2 (en) Small molecule modulators of PanK
KR20130122531A (ko) Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６­메틸니코틴아미드
WO2019133634A1 (en) Small molecule modulators of pantothenate kinases
RU2764652C2 (ru) Низкомолекулярные модуляторы пантотенаткиназ
HK40006981A (en) Small molecule modulators of pantothenate kinases
CA3025260C (en) Small molecule modulators of pantothenate kinases
BR112018076441B1 (pt) Moduladores de molécula pequena de pantotenato quinases e seus usos
US20130252943A1 (en) Bicyclic oxazole lactams as allosteric modulators of mglur5 receptors
RU2797123C2 (ru) Низкомолекулярные модуляторы пантотенаткиназ
HK40006981B (en) Small molecule modulators of pantothenate kinases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006981

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Tennessee,USA

Patentee after: St Jude Children's Research Hospital Ltd.

Address before: Tennessee,USA

Patentee before: ST. JUDE CHILDREN'S RESEARCH Hospital